Quick Facts at a Glance
- Recall Date
- October 8, 2025
- Hazard Level
- HIGH
- Brands
- Fasenra, AstraZeneca
- Category
- Health & Personal Care
- Sold At
- Unknown
- Geographic Scope
- 1 states
- At-Risk Groups
- GENERAL, PREGNANT, PREGNANT
What to Do Now
Use this page like a recall checklist: verify the product first, then act on the official remedy.
Immediate steps
- 1Stop using the product until you confirm whether it is included in the recall.
- 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
- 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
- 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.
Check these identifiers
- Brand
- Fasenra, AstraZeneca
- Product type
- Monoclonal antibody injection (benralizumab)
- Model numbers
- Lot YJ0152
- UPC codes
- 0310-1730, 0310-1830, 0310-1745, 0310-1730-30, 0310-1730-85, 0310-1830-30, 0310-1830-85, 0310-1745-01 +1 more
- Sold at
- Unknown
- Where affected
- ALL
Recall Timeline
Key dates and source checks for this recall record.
Recall announced
October 8, 2025
Reported by FDA DRUG
October 22, 2025
RecallRadar source check
April 18, 2026
Consumer action
Use the official remedy and keep documentation.
Hazard Information
Lack of Assurance of Sterility:
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact ASTRAZENECA PHARMACEUTICALS or your healthcare provider for guidance. Notification method: E-Mail
About This Product
Fasenra is a prescription monoclonal antibody used to treat eosinophilic asthma. It is administered by healthcare professionals via injection.
Why This Is Dangerous
Lack of sterility assurance means the syringe could be contaminated, posing a risk of infection to patients.
Industry Context
This recall is not described as part of a broader industry pattern.
Real-World Impact
The 916 syringes in Lot YJ0152 are distributed nationwide. Immediate cessation of use is required to avoid potential infection and supply disruption for patients relying on this therapy.
Practical Guidance
How to identify if yours is affected
- Check NDC 0310-1730-30 on the syringe label
- Check Lot number YJ0152 on the packaging
- Verify product is Fasenra 30 mg/mL in a single-dose pre-filled syringe
Where to find product info
Recall notice email from AstraZeneca and FDA recall page D-0028-2026
What timeline to expect
No timeline is provided for replacement or resolution in the notice
If the manufacturer is unresponsive
- Document all communications
- Escalate to FDA Consumer Product Safety Commission or state health department if the company is unresponsive
- Consider seeking medical guidance from a healthcare provider while waiting for resolution
How to prevent similar issues
- Verify lot and NDC before administration of any biologic injection
- Know recall contact channels and keep email notifications
- Use official recall notices for guidance when handling biologic medications
Documentation advice
Keep copies of the recall notice, all correspondence with AstraZeneca, and the packaging/labels showing NDC and lot numbers
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Product Details
NDC 0310-1730-30; Lot YJ0152; Quantity 916; Distribution Nationwide in the U.S.; Manufactured by AstraZeneca AB, Sweden; Distributed by AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850.
Reported Incidents
No injuries or incidents have been reported.
Key Facts
- Nationwide distribution in the U.S.
- Immediate action required
- Recall notification by email
Browse More Recalls
Safety Guide
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet Alerts for Health & Personal Care Recalls
Get instant alerts for recalls that affect you. Free forever.
